

XX Valenzuela D, Yuan O, Hoffman H, Hall J, Rapleyko P;
 PI WPI; 2000-638211/61.
 DR N-PSDB; AAC59829.
 DR
 XX
 PT Novel proteins and polypeptides useful for the treatment of e.g.
 PT multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis,
 PT cancer, Alzheimer's disease, Parkinson's disease, stroke, anemia and
 PT ulcers

PS Claim 92; Page 441-442; 493pp; English.

XX
 CC This invention relates to 59 human secreted proteins and the nucleotide
 CC sequences encoding them. Sequences AAC59788-C59846 and AAB34687-B34745
 CC represent the proteins and their encoding nucleotide sequences, and
 CC sequences AAB34746-B34771 represent fragments of the proteins. Probes
 CC for the DNA sequences are represented by sequences AAC59847-C59956. The
 CC proteins exhibit neuroprotective, dermatological, immunosuppressive,
 CC antiinflammatory, antianaemic, nootropic, antiparkinsonian,
 CC cerebroprotective, haemostatic, vulnerary, cytostatic, antiproliferative,
 CC antibacterial, virucide, and fungicide activity. The proteins and
 CC nucleotide sequences are useful as nutritional sources or supplements
 CC and in research. The proteins are useful for treating immune deficiency
 CC and disorders, which may be genetic or resulting from infections,
 CC autoimmune disorders such as multiple sclerosis, systemic lupus
 CC erythematosus, rheumatoid arthritis, and for treating myeloid or lymphoid
 CC cell deficiencies such as anaemias by regulating haematopoiesis. The
 CC proteins are also useful in compositions for bone, cartilage, tendon,
 CC ligament and/or nerve tissue growth or regeneration, for wound healing,
 CC tissue repair and replacement and in the treatment of central and
 CC ulcers. Other uses include in the treatment of central and
 CC peripheral nervous system and neuropathies such as Alzheimer's and
 CC Parkinson's diseases and Shy-Drager syndrome, and mechanical and
 CC traumatic disorders, such as spinal cord disorders, head trauma and
 CC stroke. The proteins may also be used as a contraceptive, and for
 CC treating coagulation disorders, such as haemophilias. The protein and
 CC nucleotide sequences with cadherin activity are useful for treating
 CC cancer. Other uses for the protein include for inhibiting the growth,
 CC infection or function of, or killing, infectious agents such as bacteria,
 CC virus, fungi and other parasites, for effecting bodily characteristics
 CC such as height, weight, hair colour, effecting biotrans or cardiac
 CC cycles or rhythms, effecting metabolism, catabolism, anabolism,
 CC processing, utilization, storage or elimination of dietary fat, lipid,
 CC protein, carbohydrate, vitamins, minerals, cofactors, effecting
 CC behavioural characteristics, providing analgesic effects and for treating
 CC hyperproliferative disorders such as psoriasis.

XX Sequence 119 AA:

Query Match 100.0%; Score 644; DB 21; Length 119;
 Best local Similarity 100.0%; Pred. No. 1.7e-66;
 Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKVLISSLLLLPLMLMSVSSSLNPGVARGHRDQASRRWLOEGGQECCKDWFLRAP 60
 DB 1 MKVLISSLLLLPLMLMSVSSSLNPGVARGHRDQASRRWLOEGGQECCKDWFLRAP 60
 QY 61 RRRFMYVSGLPKQCCPDHFKGNVKKTRRORHRRKPKKHSRACQFLKCOLRSFALPL 119
 DB 61 RRRFMYVSGLPKQCCPDHFKGNVKKTRRORHRRKPKKHSRACQFLKCOLRSFALPL 119

RESULT 2
 AA82453

ID AAY82453 standard; Protein: 119 AA.

XX AAY82453;

XX 30-JUN-2000 (first entry)

XX Human TGC-440 secretory protein SEQ ID NO:1.

KW TGC-440; secretory protein; immunological disease; infectious disease;
 KW pulmonary function disorder; hepatic function disorder; nephrotropic;
 KW gastrointestinal function disorder; antiinflammatory; immunomodulatory;
 KW virucide; hepatotropic; antistimatic; antibacterial; vaccine;
 KW hepatitis; nephritis; influenza; asthma; pulmonary hypertension;
 KW pneumonia; Helicobacter pylori infection.

OS Homo sapiens.

PN WO200014226-A1.

PD 16-MAR-2000.

PF 02-SEP-1999; 99WO-JP04765.

PR 03-SEP-1998; 98JP-0250108.

PA (TAKE) TAKEDA CHEM IND LTD.

PI Itoh Y, Ogi K, Tanaka H, Kitada C;

DR WPI; 2000-256978/72.

DR N-PSDB; AAA08343, AAA08344.

PT Secretory protein TGC440, antibodies to it and compounds promoting or
 PT inhibiting its activity for diagnosis and treatment of diseases of the
 PT immune system, lung, kidney, liver and intestinal system

PS Claim 1; Fig 1; 86pp; Japanese.

XX
 CC The present sequence represents a human secretory protein designated
 CC TGC-440. TGC-440 has antiinflammatory, nephrotropic, immunomodulatory,
 CC virucide, hepatotropic, antistimatic and antibacterial activities,
 CC and can be used in vaccines. TGC-440 and the polynucleotide sequence
 CC encoding it can be used to treat, prevent and diagnose immunological,
 CC lung, liver, kidney or gastrointestinal disorders and infectious
 CC diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,
 CC pulmonary hypertension, and Helicobacter pylori infection. An antibody
 CC immunospecific for TGC-440 is also useful in the above treatment and
 CC diagnosis, and also for quantifying the amount of TGC-440 in a liquid
 CC specimen.

XX Sequence 119 AA:

Query Match 100.0%; Score 644; DB 21; Length 119;
 Best local Similarity 100.0%; Pred. No. 1.7e-66;
 Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKVLISSLLLLPLMLMSVSSSLNPGVARGHRDQASRRWLOEGGQECCKDWFLRAP 60
 DB 1 MKVLISSLLLLPLMLMSVSSSLNPGVARGHRDQASRRWLOEGGQECCKDWFLRAP 60
 QY 61 RRRFMYVSGLPKQCCPDHFKGNVKKTRRORHRRKPKKHSRACQFLKCOLRSFALPL 119
 DB 61 RRRFMYVSGLPKQCCPDHFKGNVKKTRRORHRRKPKKHSRACQFLKCOLRSFALPL 119

RESULT 3

ID AAY87317 standard; Protein: 119 AA.

XX AAY87317;

XX 11-MAY-2000 (first entry)

XX Human signal peptide containing protein HSP-94 SEQ ID NO:94.

KW Human; signal peptide-containing protein; HSP; diagnosis; cancer;
 KW inflammation; cardiovascular disease; anticancer; anti-inflammatory;
 KW antimicrobial; neuroprotective; cardiovascular; hepatotropic;
 KW antistimatic; gene therapy; cell proliferation; neurological disorder;
 KW reproductive disorder; developmental disorder; arteriosclerosis;
 KW cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;

KW asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;
 KM Parkinson's disease; Huntington's disease; ovulatory defect;
 KM muscular dystrophy.

XX Homo sapiens.

XX WO200000610-A2.

XX 06-JAN-2000.

XX 25-JUN-1999; 99WO-US14484.

XX 26-JUN-1998; 98US-0090762.

XX 31-JUL-1998; 98US-0094983.

XX 01-OCT-1998; 98US-0102686.

XX 11-DEC-1998; 98US-0112129.

XX (INCY-) INCYTE PHARM INC.

XX Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR;
 PI Akerblom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;
 PI Bandman O;

XX WPI: 2000-160673/14.

XX N-PSDB: AA298202.

XX New human signal peptide-containing proteins useful in treatment,
 PT prevention and diagnosis of e.g. cancer, inflammation and
 PT cardiovascular disease

XX Claim 1; Page 220-221; 327pp; English.

XX AA298109 to AA298242 encode AA2987224 to AA2987357 which represent the
 CC human signal peptide-containing proteins HSP-1 to HSP-134. HSPs have
 CC anticancer, anti-inflammatory, antimicrobial, neurotropic, hepatotropic,
 CC neuroprotective, cardiovascular and antiasthmatic activities, and can
 CC be used in gene therapy. HSPs can be used to treat or prevent disorders
 CC associated with decreased activity or function of HSP. Antagonists of
 CC HSP are used to treat or prevent disorders associated with increased
 CC activity or function of HSP. Such diseases include cell proliferation
 CC (including cancer), inflammation, cardiovascular, neurological,
 CC reproductive or developmental disorders, (e.g. arteriosclerosis,
 CC cirrhosis, psoriasis, acquired immune deficiency syndrome, congestive or
 CC asthma, Crohn's disease, microbial or other infections, congenital or
 CC ischemic heart disease, Alzheimer's, Parkinson's or Huntington's
 CC diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSP
 CC nucleic acids can be used for the recombinant production of HSP, for
 CC detecting HSP in standard hybridisation and amplification assays (for
 CC diagnosis and monitoring), in gene therapy, as antisense,
 CC triplex-forming or ribozyme therapeutics, for detecting related sequences
 CC or genetic variations, and for chromosomal mapping. HSP are also used to
 CC raise specific antibodies (Ab) and to screen for agonists and
 CC antagonists (potential therapeutic agents). Ab are used to diagnose, or
 CC monitor, HSP-related diseases (in usual immunoassays), as therapeutic
 CC antagonists, in competitive drug screens, and for purification of HSP
 CC from natural sources.

XX Sequence 119 AA:

Query Match 100.0%; Score 644; DB 21; Length 119;
 Best Local Similarity 100.0%; Pred. No. 1.7e-66;
 Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKVLISSLLPLMLSMSSSSINPGVARGHRGASRRWLQEGGDECKMFLRAP 60
 Db 1 MKVLISSLLPLMLSMSSSSINPGVARGHRGASRRWLQEGGDECKMFLRAP 60
 QY 61 RRKEMTVSGLPKQPCDHFEGSNYKTRHQRHNRKPKMHSRACQFLKOCOLRSFALPL 119
 Db 61 RRKEMTVSGLPKQPCDHFEGSNYKTRHQRHNRKPKMHSRACQFLKOCOLRSFALPL 119

RESULT 4

AA298668
 ID AA298668 standard; protein; 119 AA.

XX AC AA298668;

XX 05-APR-2000 (first entry)

XX Membrane-bound protein PRO842.

XX Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;
 KW pharmaceutical; receptor immunoadhesin; gene mapping.

XX Homo sapiens.

XX WO9963088-A2.

XX 09-DEC-1999.

XX 02-JUN-1999; 99WO-US12252.

XX 02-JUN-1998; 98US-0087607.

XX 02-JUN-1998; 98US-0087609.

XX 02-JUN-1998; 98US-0087759.

XX 03-JUN-1998; 98US-0087827.

XX 04-JUN-1998; 98US-0088021.

XX 04-JUN-1998; 98US-0088025.

XX 04-JUN-1998; 98US-0088028.

XX 04-JUN-1998; 98US-0088029.

XX 04-JUN-1998; 98US-0088030.

XX 04-JUN-1998; 98US-0088033.

XX 04-JUN-1998; 98US-0088167.

XX 05-JUN-1998; 98US-0088202.

XX 05-JUN-1998; 98US-0088212.

XX 05-JUN-1998; 98US-0088217.

XX 09-JUN-1998; 98US-0088655.

XX 10-JUN-1998; 98US-0088722.

XX 10-JUN-1998; 98US-0088730.

XX 10-JUN-1998; 98US-0088734.

XX 10-JUN-1998; 98US-0088738.

XX 10-JUN-1998; 98US-0088740.

XX 10-JUN-1998; 98US-0088741.

XX 10-JUN-1998; 98US-0088742.

XX 10-JUN-1998; 98US-0088810.

XX 10-JUN-1998; 98US-0088811.

XX 10-JUN-1998; 98US-0088824.

XX 10-JUN-1998; 98US-0088825.

XX 10-JUN-1998; 98US-0088826.

XX 11-JUN-1998; 98US-0088858.

XX 11-JUN-1998; 98US-0088861.

XX 11-JUN-1998; 98US-0088863.

XX 11-JUN-1998; 98US-0088876.

XX 12-JUN-1998; 98US-0089090.

XX 12-JUN-1998; 98US-0089105.

XX 16-JUN-1998; 98US-0089440.

XX 16-JUN-1998; 98US-0089512.

XX 16-JUN-1998; 98US-0089514.

XX 17-JUN-1998; 98US-0089532.

XX 17-JUN-1998; 98US-0089538.

XX 17-JUN-1998; 98US-0089598.

XX 17-JUN-1998; 98US-0089599.

XX 17-JUN-1998; 98US-0089600.

XX 17-JUN-1998; 98US-0089653.

XX 18-JUN-1998; 98US-0089601.

XX 18-JUN-1998; 98US-0089607.

XX 18-JUN-1998; 98US-0089908.

XX 19-JUN-1998; 98US-0089947.

XX 19-JUN-1998; 98US-0089948.

XX 19-JUN-1998; 98US-0089952.

XX 22-JUN-1998; 98US-0090246.

XX 22-JUN-1998; 98US-0090252.

XX 22-JUN-1998; 98US-0090254.

XX 23-JUN-1998; 98US-0090349.

CC Chromosomal and gene mapping, and in the generation of anti-sense RNA
CC and DNA. They may also be used to produce transgenic animals which are
CC used to develop and screen therapeutically useful reagents. The PRO
CC nucleotide and protein sequence can be used for tissue typing and in
CC treating cancer. Anti-PRO antibodies can be used in diagnostic assays.
CC AAF44270 to AAF44470 represent PCR primers and hybridisation probes used
CC in the isolation of human PRO sequences. AAF44087 to AAF44269 and
CC AAF65154 to AAF65300 represent human PRO polynucleotide and protein
CC sequences given in the exemplification of the present invention.

XX Sequence 119 AA;

Query Match 100.0%; Score 644; DB 22; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.7e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MKVLSSLLPLMLMSVSSSLNPGVARGHRRGASRRMLQEGGCECKDMLRAP 60
DB 1 MKVLSSLLPLMLMSVSSSLNPGVARGHRRGASRRMLQEGGCECKDMLRAP 60
OY 61 RRFMTVSGLPKRCPCDHFKNVKTTRHQRHRRKPKNSRACQDFLKCQQLRSFALPL 119
DB 61 RRFMTVSGLPKRCPCDHFKNVKTTRHQRHRRKPKNSRACQDFLKCQQLRSFALPL 119

RESULT 9
ID AAY82454 standard; Protein; 97 AA.
AC AAY82454;

XX 30-JUN-2000 (first entry)
DE Mature human TGC-440 secretory protein SEQ ID NO:7.

XX TGC-440: secretory protein; immunological disease; infectious disease;
XX pulmonary function disorder; hepatic function disorder; nephrotropic;
XX gastroenteric function disorder; antiinflammatory; immunomodulatory;
XX virucide; hepatotropic; antidiarrhetic; antibacterial; vaccine;
XX hepatitis; nephritis; influenza; asthma; pulmonary hypertension;
XX pneumonia; Helicobacter pylori infection.

OS Homo sapiens.
XX WO200014226-A1.

XX 16-MAR-2000.

XX 02-SEP-1999; 99WO-JP04765.

XX 03-SEP-1998; 98JP-0250108.

XX (TAKE) TAKEDA CHEM IND LTD.

XX Itoh Y, Ogi K, Tanaka H, Kitada C;
XX WPI: 2000-256978/22.

XX N-PSDB: AAA08345.

XX Secretory protein TGC440, antibodies to it and compounds promoting or
XX inhibiting its activity for diagnosis and treatment of diseases of the
XX immune system, lung, kidney, liver and intestinal system
XX Dislosure; Page 80; 86pp; Japanese.

XX The present sequence represents the mature human secretory protein
XX TGC-440. TGC-440 has antiinflammatory, nephrotropic, immunomodulatory,
XX vitrucide, hepatotropic, antidiarrhetic and antibacterial activities,
XX and can be used in vaccines. TGC-440 and the polynucleotide sequence
XX encoding it can be used to treat, prevent and diagnose immunological,
XX lung, liver, kidney or gastrointestinal disorders and infectious
XX diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,
XX pulmonary hypertension, and Helicobacter pylori infection. An antibody

CC Immunospecific for TGC-440 is also useful in the above treatment and
CC diagnosis, and also for quantifying the amount of TGC-440 in a liquid
CC specimen.
XX Sequence 97 AA;

Query Match 85.1%; Score 548; DB 21; Length 97;
Best Local Similarity 100.0%; Pred. No. 1.6e-55;
Matches 97; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 23 SLNPGVARGHRRGASRRMLQEGGCECKDMLRAPRRKMTVSGLPKRCPCDHFNG 82
DB 1 SLNPGVARGHRRGASRRMLQEGGCECKDMLRAPRRKMTVSGLPKRCPCDHFNG 60
OY 83 NVKTRHQRHRRKPKNSRACQDFLKCQQLRSFALPL 119
DB 61 NVKTRHQRHRRKPKNSRACQDFLKCQQLRSFALPL 97

RESULT 10
ID AAW83953 standard; Protein; 93 AA.
AC AAW83953;

XX 28-JAN-1999 (first entry)
DE Polypeptide encoded by gene 7 clone HUPDJ64.

XX Secreted protein; gene therapy; protein therapy; diagnosis; treatment;
XX central nervous system; CNS; immune system; cancer; trauma; liver;
XX reproductive disorder; congenital malformation; degenerative disease;
XX inflammatory disease; neoplasia; metabolic disorder; testis; placenta;
XX brain; T cell; spleen; lung; heart; thymomysarcoma; endocrine system;
XX endocrinopathy; endocrine polyglandular syndrome; endocrine system;
XX endocrine ophthalmopathy; osteoclastoma; bacterial infection; bone.

OS Homo sapiens.
XX WO9845712-A2.

XX 15-OCT-1998.

XX 07-APR-1998; 98WO-US06801.

XX 30-MAY-1997; 97US-0048184.

XX 08-APR-1997; 97US-0042726.

XX 08-APR-1997; 97US-0042727.

XX 08-APR-1997; 97US-0042728.

XX 08-APR-1997; 97US-0042754.

XX 08-APR-1997; 97US-0042825.

XX 30-MAY-1997; 97US-0048068.

XX 30-MAY-1997; 97US-0048070.

XX (HUMA-) HUMAN GENOME SCI INC.
XX Feng P, NI J, Rosen CA, Ruben SM, Yu G;

XX WPI: 1998-594496/50.

XX New isolated human genes and secreted polypeptide(s) they encode -
XX useful for the diagnosis and treatment of e.g. cancers, CNS
XX disorders, immune system disorders, inflammatory disease and
XX bacterial infections
XX Dislosure; Page 10; 142pp; English.
XX This represents a polypeptide encoded by the nucleic acid molecule
XX designated Gene 7 from the human cDNA clone HUPDJ64 (deposited
XX as clone ATCC 97955 and ATCC 209074) which encodes a human secreted
XX protein of the invention. The gene is expressed primarily in liver,
XX spleen, bone marrow and to a lesser extent in amygdala and is useful as
XX reagents for differential identification of tissues in a biological

SECRETED: 53 (P126)

SD Sequence 93 AA;

Query Match	81.8%;	Score 527;	DB 19;	Length 93;
Best Local Similarity	100.0%;	Pred. No. 4.2e-53;		
Matches 83: Conservative	0.0;	Mismatches	0.0;	Truncated

0y 27 GVARKHRDRGASRRMTLEGGECECKDWTLRAPRRKFMVSGLPKKQPCDHFEGNVKK 86
Db 1 GVAGHRDRGASRRMTLEGGECECKDWTLRAPRRKFMVSGLPKKQPCDHFEGNVKK 600

```

Qy      87 TRHQRRHRRKPNKHSRACQOFLKQCQLRSFALPL 119
        |||||
Db      61 TRHQRRHRRKPNKHSRACQOFLKQCQLRSFALPL 93

```

RESULT 11
AAV82457
ID AAV82457 standard; Protein; 119 AA

AC AAY82457;

DT 30-JUN-2000 (first entry)

DE Mouse TGC-440 secretory protein SEQ ID NO:3.

KW TGC-440 secretory protein; immunological disease; infectious disease;
KW pulmonary function disorder; hepatic function disorder; nephrotropic;
KW gastrointestineal function disorder; antiinflammatory; immunomodulatory;
KW virulence; hepatotropic; antiaesthetic; antibacterial; vaccine;
KW hepatitis; nephritis; influenza; asthma; pulmonary hypertension;
KW pneumonia; *Helicobacter pylori* infection.

05 Mus sp.

PN W0200014226-A1.

PD 16-MAR-2000.

PF 02-SEP-1999; 99WO-JP04765.

PR 03-SEP-1998; 98JP-0250108.

PA (TAKE) TAKEDA CHEM IND LTD.

PI Itoh Y, Ogi K, Tanaka H, Kitada C;

DR WPI; 2000-256978/22

XX

PT Secretory protein TGCG40, antibodies to it and compounds promoting or
PT inhibiting its activity for diagnosis and treatment of diseases of the
PT immune system, lung, kidney, liver and intestinal system -
XX

PS Claim 1; Fig 3; 86pp; Japanese.

The present description represents a mouse secretory protein designated TGC-440. TGC-440 has antinflammatory, nephrotropic, immunomodulatory, virucide, hepatotropic, antihelminthic and antibacterial activities, and can be used in vaccines. TGC-440 and the polynucleotide sequence encoding it can be used to treat, prevent and diagnose immunological, lung, liver, kidney or gastrointestinal disorders and infectious diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia, pulmonary hypertension, and Helicobacter pylori infection. An antibody immunospecific for TGC-440 is also useful in the above treatment and diagnosis, and also for quantifying the amount of TGC-440 in a liquid specimen.

Sequence 119 AA;

Query Match	70.8%;	Score 456;	DB 21;	Length 119;
Best Local Similarity	71.4%;	Pred. No. 8.8e-45;		
Matches	85;	Conservative	9;	Mismatches 25; Indels 0; Gaps 0

QY 1 MKVLISSLLLLPLMLMSVSSSLNPGVARGHRDRGQASRRWLQEGGQCECECKDWFLRAP 60

[illegible]

RESULT 12

ID	AY82458 standard; Protein; 97 AA.
1	1
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9
10	10
11	11
12	12
13	13
14	14
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45
46	46
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66
67	67
68	68
69	69
70	70
71	71
72	72
73	73
74	74
75	75
76	76
77	77
78	78
79	79
80	80
81	81
82	82
83	83
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99
100	100

AC AAY82458;

DT 30-JUN-2000 (first entry)

DE Mature mouse TGC-440 secretory protein SEQ ID NO:9.

.KM TSG-440;secretory protein; immunological disease; infectious disease;
 .KM pulmonary function disorder; hepatic function disorder; nephrotic
 .KM gastrointestinal function disorder; antiinflammatory; immunomodulatory
 .KM virulence; hepatotropic; antiaesthetic; antibacterial; vaccine;
 .KM hepatitis; nephritis; influenza; asthma; pulmonary hypertension;
 .KM pneumonia; *Helicobacter pylori* infection.

OS Mus sp

PN WO200014226-A1.

PD 16-MAR-2000.

PF 02-SEP-1999; 99WO-JP04765.

PR 03-SEP-1998; 98JP-0250108.

PA (TAKE) TAKEDA CHEM IND LTD.
 22

PI Itoh Y, Ogi K, Tanaka H, Kitada C;
yy

DR WPI; 2000-256978/22.

XX
XX
DE

C O C + C : S O + T F

PT Inhibiting its ac

Disclosure: Page 81-82; 86pp; Japanese.

CC The present sequence represents the mature mouse secretory protein
CC TGC-440. TGC-440 has antiinflammatory, nephroprotective, immunomodulatory
CC virucide, hepatotropic, antihelminthic and antibacterial activities,
CC and can be used in vaccines. TGC-440 and the polynucleotide sequence